Research & Academia

Neurodiagnostics Symposium

Wednesday, September 23 at 9:00 am - 5:00 pm Add to Calendar 2026-09-23 09:00:00 2026-09-23 17:00:00 Neurodiagnostics Symposium Neurodiagnostics Symposium Advancing Biomarker Discovery and Application This in-person event aims to convene the neurosciences community working on biomarker discovery to foster connection, forge collaborations, and provide insights into the process of advancing early candidate biomarkers to clinical use. Registration for the event has reached capacity. Please contact Lauren de Remer ([email protected]) to be placed on a waitlist. Additionally, please note that walk-ins will not be accommodated. Program Overview Registration begins at 8:30am | Coffee and breakfast provided Morning Sessions | 9:00am–12:10pm Welcome and Introduction by Bill Seeley and Michael Wilson Session 1: Biomarker Discovery "Proteomic Approaches to Understanding Neurobiology" Danielle Swaney "Beyond Encephalitis: Recurrent Autoantibody Signals in Psychotic Spectrum Disorders" Christopher Bartley "From Biomarker to Causality: Genetic Drug Target Validation in Humans" Iyas Daghlas Session 2: Validation Strategies & Targeted Assay Development "Epitope Discovery and Validation Identify Epstein-Barr Virus Antibody Profiles Linked to Multiple Sclerosis Risk" Krista McCutcheon "Discovery to Deployment Pipeline for Soluble Protein Markers" Ahmed Abdelhak (Including work from collaborator Julio Rojas-Martinez) "Amyloid Amplification Assays: Past, Present, and Future" Michael Metrick Lunch provided from 12:10-1:10pm Afternoon Sessions | 1:10pm-4:00pm Session 3: Clinical Implementation "Clinical Implementation of Novel Biomarkers: You Are Not Trained for This Journey" Alan Wu "Does It Work In the Real World? Designing New Biomarker Studies for Generalizability" Elizabeth Rose Mayeda Session 4: Scalability & Academic-Industry Partnerships "Immunectra: The Journey From UCSF Clinical Research to Founding a Venture-Scale Company" Caroline Vissers "Neurodiagnostics: The State of the Market From the University Perspective" David Morris "It’s Not All Over Until the Patients Benefit: The Case for Founding a Company Around Your Discovery" Douglas Crawford Reception | 4-5pm 675 18th Street Pritzker Building, Auditorium San Francisco, CA 94107 United States View on Map UCSF Weill Institute For Neurosciences Department Of Neurological Surgery Department Of Neurology Department Of Psychiatry And Behavioral Sciences [email protected] America/Los_Angeles public

675 18th Street
Pritzker Building, Auditorium
San Francisco, CA 94107
United States

View on Map

Neurodiagnostics Symposium
Advancing Biomarker Discovery and Application

This in-person event aims to convene the neurosciences community working on biomarker discovery to foster connection, forge collaborations, and provide insights into the process of advancing early candidate biomarkers to clinical use.

Registration for the event has reached capacity. Please contact Lauren de Remer ([email protected]) to be placed on a waitlist. Additionally, please note that walk-ins will not be accommodated.

Program Overview

Registration begins at 8:30am | Coffee and breakfast provided

Morning Sessions | 9:00am–12:10pm

Welcome and Introduction by Bill Seeley and Michael Wilson

Session 1: Biomarker Discovery
"Proteomic Approaches to Understanding Neurobiology"
Danielle Swaney
"Beyond Encephalitis: Recurrent Autoantibody Signals in Psychotic Spectrum Disorders"
Christopher Bartley
"From Biomarker to Causality: Genetic Drug Target Validation in Humans"
Iyas Daghlas

Session 2: Validation Strategies & Targeted Assay Development
"Epitope Discovery and Validation Identify Epstein-Barr Virus Antibody Profiles Linked to Multiple Sclerosis Risk"
Krista McCutcheon
"Discovery to Deployment Pipeline for Soluble Protein Markers"
Ahmed Abdelhak (Including work from collaborator Julio Rojas-Martinez)
"Amyloid Amplification Assays: Past, Present, and Future"
Michael Metrick

Lunch provided from 12:10-1:10pm

Afternoon Sessions | 1:10pm-4:00pm

Session 3: Clinical Implementation
"Clinical Implementation of Novel Biomarkers: You Are Not Trained for This Journey"
Alan Wu
"Does It Work In the Real World? Designing New Biomarker Studies for Generalizability"
Elizabeth Rose Mayeda

Session 4: Scalability & Academic-Industry Partnerships
"Immunectra: The Journey From UCSF Clinical Research to Founding a Venture-Scale Company"
Caroline Vissers
"Neurodiagnostics: The State of the Market From the University Perspective"
David Morris
"It’s Not All Over Until the Patients Benefit: The Case for Founding a Company Around Your Discovery"
Douglas Crawford

Reception | 4-5pm

Discovery
Neuroscience
Translational
Biomarkers
Diagnostics